Dale Bredesen, MD, is an internationally recognized neurologist with specialty expertise in the mechanisms of neurodegenerative diseases. He is the senior director of Precision Brain Health at Pacific Neuroscience Institute® and the Chief Scientific Officer at Apollo Health.
Guided by his philosophy and belief that Alzheimer’s disease it is not just preventable, but reversible, Dr. Bredesen’s innovative research has helped explain the physical mechanism behind the erosion of memory seen in Alzheimer’s disease. His decades of clinical study and neurological research have opened the door to new approaches of treatment leading to the ReCODE Protocol™. Also known as the Bredesen Protocol, this methodology has emerged as a viable attempt to prevent, arrest, and reverse symptoms of cognitive decline associated with conditions such as Alzheimer’s disease, dementias, and mild cognitive impairment.
Dr. Bredesen earned his medical degree from Duke University Medical Center and served as Chief Resident in Neurology at the University of California, San Francisco (UCSF), before joining Nobel laureate Stanley Prusiner’s laboratory at UCSF as an NIH Postdoctoral Fellow. He held faculty positions at UCSF, UCLA, and the University of California, San Diego. Dr. Bredesen also directed the Program on Aging at the Burnham Institute before joining the Buck Institute in 1998 as founding President and CEO.
With over thirty patents to his name, Dr. Bredesen has contributed significantly to medical knowledge and literature. Notably, he put much of his findings and research into the 2017 New York Times‘ Best-Seller, The End of Alzheimer’s.
Additional book titles included The End of Alzheimer’s Program and The First Survivors of Alzheimer’s, the latter of which presents the stories of seven individuals who reversed their cognitive decline using the ReCODE Protocol.